<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="231298">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067119</url>
  </required_header>
  <id_info>
    <org_study_id>VACTDC (completed)</org_study_id>
    <nct_id>NCT00067119</nct_id>
  </id_info>
  <brief_title>Vascular Access Clinical Trials Data Coordinating Center</brief_title>
  <official_title>1) Clopidogrel Prevention of Early AV Fistula Thrombosis (IND 64169) 2) Aggrenox Prevention of Access Stenosis (IND 64,202)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tyler Nephrology Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vascular Surgery Associates LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fistula Study: The objective of the study is to determine whether clopidogrel reduces the
      early failure rate of native AV fistulae.

      Graft Study: The objective of the study is to determine whether Aggrenox
      (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous
      grafts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <enrollment type="Anticipated">1284</enrollment>
  <condition>Kidney Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggrenox</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Fistula Study Protocol

        Inclusion Criteria:

          -  Age 18-21 depending on state regulations

          -  Life expectancy of at least six months

          -  Chronic renal failure with anticipated start of hemodialysis within six months of
             enrollment, or current dialysis dependence

          -  Planned creation of native upper extremity AV fistula

          -  The patient is not on aspirin, or the patient is on aspirin but has not had a
             myocardial infarction or a cerebrovascular accident within the past 12 months.

          -  The patient is expected to stay at a participating dialysis facility for at least 6
             months.

          -  The patient's physician(s) will allow the patient to participate.

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  Women must not be pregnant, breastfeeding, or plan to be pregnant during the course
             of the study.

          -  The presence of ongoing bleeding.

          -  The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's
             disease).

          -  Recent bleeding episode requiring transfusion within 12 weeks of entry.

          -  The presence of acute ulcer disease. Acute ulcer disease is defined as a new
             diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the
             initiation of treatment with proton pump inhibitors, H2 blockers or therapy for
             Helicobacter pylori within three months prior to obtaining consent.

          -  A condition which prohibits discontinuation of anticoagulant drugs, aspirin, or
             nonsteroidal anti-inflammatory drugs dudring the six week study drug administration
             period. Use of heparin during dialysis is allowed.

          -  Required use of oral or intravenous glucocorticoids at a dose greater than the
             equvalent of prednisone 15 mg per day during the six week study drug administration
             period.

          -  Current unstable angina.

          -  Required use of clopidogrel.

          -  Known hypersensitivity to clopidogrel.

          -  Medical considerations making anti-platelet therapy dangerous.

          -  Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg
             or diastolic blood pressure in excess of 115 mm Hg at the time of enrollment.

          -  Baseline platelet count less than 75,000/mm3.

          -  Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or
             bleeding varices.

          -  Current problem with substance abuse.

          -  Concurrent participation in another medical intervention trial.

          -  Anticipated non-compliance with medical care based on physician judgment.

          -  Patient refusal.

        Graft Study Protocol

        Inclusion criteria:

          -  Age 18-21 depending on state regulations

          -  Life expectancy of at least six months

          -  Chronic renal failure with anticipated start of hemodialysis within six months of
             enrollment, or current dialysis dependence

          -  A new or planned AV graft placed in any location for the purpose of hemodialysis.
             (Any type of graft material and any configuration of the access is acceptable).

          -  The patient is expected to stay at a participating dialysis facility for at least 6
             months.

          -  The patient's physician(s) will allow the patient to participate.

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  Women must not be pregnant, breastfeeding, or plan to be pregnant during the course
             of the study.

          -  The presence of ongoing bleeding.

          -  The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's
             disease).

          -  Recent bleeding episode requiring transfusion within 12 weeks of entry.

          -  The presence of acute ulcer disease. Acute ulcer disease is defined as a new
             diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the
             initiation of treatment with proton pump inhibitors, H2 blockers or therapy for
             Helicobacter pylori within three months prior to obtaining consent.

          -  Known allergy or adverse reaction to Aggrenox or any of its study components
             (dipyridamole and aspirin).

          -  Required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other
             antiplatelet agents other than aspirin.

          -  Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg
             or diastolic blood pressure in excess of 115 mm Hg.

          -  Baseline platelet count less than 75,000/mm3.

          -  Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or
             bleeding varices.

          -  Current problem with substance abuse.

          -  Concurrent participation in another medical intervention trial.

          -  Anticipated non-compliance with medical care based on physician judgment.

          -  Patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Kusek, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK - Telephone: 301-594-7717; Email: kusekj@ep.niddk.nih.gov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Meyers, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK - Telephone: 301-451-4901; Email: meyersc@extra.niddk.nih.gov</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kusek JW, Lawson JH, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group.. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials. 2005;2(5):413-22.</citation>
    <PMID>16317810</PMID>
  </reference>
  <reference>
    <citation>Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group.. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clin Trials. 2005;2(5):400-12.</citation>
    <PMID>16317809</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 2, 2010</lastchanged_date>
  <firstreceived_date>August 11, 2003</firstreceived_date>
  <responsible_party>
    <name_title>Catherine Meyers, MD, Project Officer</name_title>
    <organization>NIH/NIDDK</organization>
  </responsible_party>
  <keyword>Graft Failure</keyword>
  <keyword>Access Blood Flow Monitoring</keyword>
  <keyword>Clinical Trial Vascular Access</keyword>
  <keyword>Fistula Failure</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
